- Home
- OCSL vs XNCR Comparison
OCSL vs XNCR Comparison
Compare OCSL & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OCSL | XNCR |
|---|---|---|
| Founded | 2007 | 1997 |
| Country | United States | United States |
| Employees | N/A | 250 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2008 | 2013 |
Fundamental Metrics
Financial Performance| Metric | OCSL | XNCR |
|---|---|---|
| Price | $12.87 | $15.69 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $14.33 | ★ $22.78 |
| AVG Volume (30 Days) | ★ 738.7K | 730.6K |
| Earning Date | 02-03-2026 | 11-05-2025 |
| Dividend Yield | ★ 12.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $316,801,000.00 | $150,132,000.00 |
| Revenue This Year | N/A | $18.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.76 | ★ N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $12.44 | $6.92 |
| 52 Week High | $16.29 | $25.54 |
Technical Indicators
Market Signals| Indicator | OCSL | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 32.15 | 47.04 |
| Support Level | $13.53 | $16.44 |
| Resistance Level | $12.99 | $17.18 |
| Average True Range (ATR) | 0.20 | 0.97 |
| MACD | -0.10 | -0.28 |
| Stochastic Oscillator | 12.02 | 6.65 |
Price Performance
Historical ComparisonAbout OCSL Oaktree Specialty Lending Corporation
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.